A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)

• Status: Active, not recruiting
• Trial end date: 2021-09-30

Summary

The study is a phase 2 proof of concept study. The purpose of this study is to assess the efficacy and safety of Prothione™ capsules administered orally twice a day for 30 days in subjects with mild to moderate COVID-19. The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.

The issued patents relevant to Prothione™ capsules and the treatment of viral disease include: • Nutritional or Therapeutic Compositions and Methods to Increase Bodily

Glutathione Levels:

1. US Patent No. RE 42,645

2. Japanese Patent No. 5601745

3. European Patent No. 1556023

4. Canadian Patent No. 2539567

5. Australian Patent No. 2010201136

• Protective Metallothionein Analog Compounds, Their Compositions and Use

Thereof in the Treatment of Pathogenic Disease:

6. Canadian Patent No. 2963131

7. Australian Patent No. 2018279015

• Phase: Phase 2

Details

• Lead Sponsor: Prothione, LLC